Adial Pharmaceuticals AZR

Adial Pharmaceuticals adjourns meeting

Additional proxy materials

Form
DEFA14A
Filed
Importance
Routine
  1. Meeting adjourned to Oct 15, 2026
  2. Nasdaq approval pending for proposals 3-6

Written from the DEFA14A on EDGAR. Check the filing before you rely on it.

Get an email when Adial Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.